12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles

12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles

General anesthesia can be achieved through either balanced anesthesia (the co-administration of inhaled volatile agents, intravenous hypnotics, opioids, and neuromuscular blocking drugs) or Total Intravenous Anesthesia (TIVA), where hypnotic state, amnesia, and antinociception are sustained exclusively via intravenous infusions. Selecting between these modalities requires understanding pharmacokinetic modeling, context-sensitive half-times, organ clearance pathways, and specialized surgical requirements.

---

1. The Triad of General Anesthesia & Balanced Anesthetic Rationale

Modern balanced general anesthesia is built upon the classic anesthetic triad:

1. Hypnosis / Amnesia / Unconsciousness: Provided by volatile agents (Sevoflurane, Desflurane, Isoflurane) or IV hypnotics (Propofol).
2. Analgesia / Antinociception: Provided by opioids (Fentanyl, Remifentanil, Sufentanil), NMDA antagonists (Ketamine), or $\alpha_2$-adrenergic agonists (Dexmedetomidine).
3. Muscle Relaxation / Immobility: Provided by nondepolarizing neuromuscular blocking agents (Rocuronium, Cisatracurium, Vecuronium).

                    [THE BALANCED ANESTHETIC TRIAD]

                              HYPNOSIS
                        (Volatiles, Propofol)
                               /      \
                              /        \
                             /  SYNERGY \
                            /            \
                   ANALGESIA ------------ IMMOBILITY
              (Opioids, Ketamine)     (NMBAs: Rocuronium)

Pharmacologic Synergy & Side-Effect Blunting

Administering targeted combinations of agents produces supra-additive (synergistic) anesthetic depth. For example, co-administering an opioid infusion (such as remifentanil or fentanyl) reduces the Minimum Alveolar Concentration (MAC) of volatile anesthetics by up to $50 - 70%$. This MAC-sparing effect permits lower volatile concentrations, minimizing dose-dependent myocardial depression, peripheral vasodilation, and prolonged emergence.

---

2. Clinical Indications for Total Intravenous Anesthesia (TIVA)

Although volatile-based balanced anesthesia is the standard of care for many routine surgical cases, TIVA is specifically indicated in several critical clinical scenarios:

+-------------------------------------------------------------------------+
|                     PRIMARY CLINICAL INDICATIONS FOR TIVA               |
+-----------------------+-------------------------------------------------+
| Clinical Scenario     | Pathophysiologic & Pharmacologic Rationale      |
+-----------------------+-------------------------------------------------+
| **Malignant           | Absolute contraindication to all halogenated    |
|   Hyperthermia (MH)** | volatile gases and succinylcholine; propofol-   |
|                       | opioid TIVA is completely non-triggering        |
| **Intraoperative      | Volatile anesthetics (>0.5 MAC) suppress        |
|   Neuromonitoring**   | cortical and spinal synaptic transmission,      |
|   (MEPs & SSEPs)      | destroying transcranial motor evoked potentials |
| **High PONV Risk**    | Propofol possesses intrinsic antiemetic actions |
|   (Apfel Score 3-4)   | via D₂ and 5-HT₃ subcortical antagonism         |
| **Laser Airway /      | Eliminates volatile gas pollution and reduces   |
|   Shared Airway**     | airway fire risk during tubeless / jet surgery  |
| **Neurosurgery /      | Volatiles cause cerebral vasodilation at >0.6   |
|   Elevated ICP**      | MAC; propofol couples CBF reduction with CMRO₂  |
|                       | reduction, maintaining intracranial compliance  |
| **Mitochondrial       | Prevents volatile-induced uncoupling of         |
|   Myopathies**        | oxidative phosphorylation                       |
+-----------------------+-------------------------------------------------+

Intraoperative Neuromonitoring (IONM) Specifics

• Motor Evoked Potentials (MEPs): Transcranial electrical stimulation of the motor cortex generates action potentials traversing the corticospinal tract to peripheral muscle recording sites. The anterior horn $\alpha$-motor neuron synapses are exceptionally sensitive to volatile anesthetics. Inhaled agents at $>0.5 \text{ MAC}$ cause profound, dose-dependent reductions in MEP amplitude ($>50%$) and prolongation of latency. NMBAs must also be avoided or tightly controlled.
• Somatosensory Evoked Potentials (SSEPs): Ascend through the dorsal column-medial lemniscal pathway. Volatile agents reduce SSEP amplitude and increase latency.
• Standard IONM TIVA Regimen: Propofol ($100 - 150 \text{ mcg/kg/min}$) + Remifentanil ($0.1 - 0.3 \text{ mcg/kg/min}$) provides deep surgical anesthesia while leaving MEP and SSEP signal quality pristine.

---

3. Pharmacokinetics of Continuous Infusions: Three-Compartment Modeling

Intravenous anesthetic distribution is best described by a three-compartment mammillary pharmacokinetic model:

• Central Compartment ($V_1$): Rapidly equilibrating blood volume and highly perfused vessel-rich group (brain, heart, liver, kidneys; represents $\approx 10%$ of body mass, receives $75%$ of cardiac output).
• Rapid Peripheral Compartment ($V_2$): Muscle and skin.
• Slow Peripheral Compartment ($V_3$): Adipose tissue and poorly perfused connective tissues.

                     [THREE-COMPARTMENT MAMMILLARY MODEL]

                             Rapid Peripheral
                             Compartment (V₂)
                                ^        |
                            k₁₂ |        | k₂₁
                                |        v
       [IV Infusion / Dose] --> CENTRAL COMPARTMENT (V₁) --> Elimination (k₁₀)
                                |        ^
                            k₁₃ |        | k₃₁
                                v        |
                             Slow Peripheral
                             Compartment (V₃)

Micro-Rate Constants & Clearance Kinetics

• $k_{10}$: Rate constant of irreversible metabolic drug elimination from the central compartment ($V_1$).
• $k_{12}, k_{21}$: Distribution rate constants between central and rapid peripheral compartments.
• $k_{13}, k_{31}$: Distribution rate constants between central and slow peripheral compartments.
• Following an IV bolus, drug concentration in $V_1$ drops precipitously primarily due to rapid redistribution into $V_2$ and $V_3$ (the distribution $\alpha$-phase), rather than immediate hepatic elimination (the elimination $\beta$-phase).

---

4. Context-Sensitive Half-Time (CSHT) & Effect-Site Equilibration ($k_{e0}$)

The elimination half-life ($t_{1/2\beta}$) is an unreliable predictor of recovery following continuous intravenous infusions because it ignores the extensive accumulation of drug in peripheral storage compartments ($V_2, V_3$).

Defining Context-Sensitive Half-Time (CSHT)

Context-Sensitive Half-Time (CSHT) is defined as the time required for the central compartment (plasma) drug concentration to decrease by $50%$ after the termination of a continuous infusion of a specified duration (the "context").

                    [CONTEXT-SENSITIVE HALF-TIME PROFILES]

      CSHT (Minutes)
       300 |
           |                                          /--- FENTANYL (Steep rise)
       240 |                                         /
           |                                        /
       180 |                                       /
           |                                      /
       120 |                                     /   /---- SUFENTANIL
           |                                    /   /
        60 |                 /-----------------/---/------ MIDAZOLAM
           |                /----------------------------- PROPOFOL (~20-30 min plateau)
         0 +---------------+---------------+---------------+-----> Infusion Duration
           0               2               4               8 (Hours)
           ............................................... REMIFENTANIL (Flat ~3-4 min)

+-------------------------------------------------------------------------+
|                     DRUG CSHT COMPARISON SUMMARY                        |
+------------------+-----------------------------+------------------------+
| Anesthetic Drug  | CSHT Profile After 4-8 hr   | Primary Mechanism      |
+------------------+-----------------------------+------------------------+
| **Remifentanil** | **Constant: 3 - 4 minutes** | Rapid hydrolysis by    |
|                  | (Context-insensitive)       | non-specific blood and |
|                  |                             | tissue esterases       |
| **Propofol**     | **Short: 20 - 30 minutes**  | High metabolic clear-  |
|                  | (Flattens due to clearance) | ance + redistribution  |
| **Sufentanil**   | Intermediate (~30-40 min)   | High clearance, slow V₃|
| **Fentanyl**     | **Prolonged: > 200 minutes**| Massive accumulation in|
|                  | (Steep exponential rise)    | fat with slow return   |
| **Midazolam**    | Prolonged (> 100 minutes)   | Hepatic saturation and |
|                  |                             | active metabolites     |
+------------------+-----------------------------+------------------------+

Effect-Site Equilibration ($k_{e0}$) & Hysteresis

The biophase (effect compartment) represents the actual site of drug action within the central nervous system. Because drug must cross the blood-brain barrier, a temporal delay (hysteresis) occurs between peak plasma concentration ($C_p$) and peak clinical effect ($C_e$).

• $k_{e0}$: The first-order rate constant describing drug exit from the effect compartment.
• $t_{1/2} k_{e0}$ (Equilibration Half-Time): Time required to achieve $50%$ equilibration between plasma and effect site ($t_{1/2} k_{e0} = \frac{\ln 2}{k_{e0}}$).
• Propofol: $t_{1/2} k_{e0} \approx 2 - 3 \text{ minutes}$ (peak clinical hypnosis at $\approx 2 \text{ minutes}$ post-bolus).
• Remifentanil: $t_{1/2} k_{e0} \approx 1 - 1.5 \text{ minutes}$ (nearly instantaneous effect-site tracking).
• Fentanyl: $t_{1/2} k_{e0} \approx 4 - 6 \text{ minutes}$.

---

5. Target-Controlled Infusion (TCI) Principles & Models

Target-Controlled Infusion (TCI) systems use computerized microprocessor-driven syringe pumps programmed with pharmacokinetic/pharmacodynamic population models to maintain a user-selected target drug concentration in either plasma ($C_p$) or the effect site ($C_e$).

+-------------------------------------------------------------------------+
|                    COMMON PROPOFOL TCI PHARMACOKINETIC MODELS           |
+--------------------+-------------------------+--------------------------+
| Model Feature      | Marsh Model             | Schnider Model           |
+--------------------+-------------------------+--------------------------+
| **Patient Inputs** | Weight only             | Age, Height, Weight,     |
|                    |                         | Lean Body Mass (LBM)     |
| **Central Volume** | Proportional to weight  | Fixed small V₁ (4.27 L)  |
|   ($V_1$)          | ($V_1 = 0.228 \text{ L/kg}$) |                      |
| **Clearance**      | Weight-proportional     | Decreases with age       |
| **Optimal Use**    | General adult population| Elderly and obese        |
|                    |                         | patients (avoids overdose|
+--------------------+-------------------------+--------------------------+

• Minto Model for Remifentanil: Incorporates age, height, weight, and lean body mass. Accounts for reduced central clearance and smaller distribution volumes in elderly patients.

---

6. Processed EEG & Depth of Anesthesia Monitoring

Processed electroencephalography (e.g., Bispectral Index / BIS, SedLine) translates raw frontal cortical electrical activity into a dimensionless index ranging from 0 to 100 to assess hypnotic depth and prevent intraoperative awareness with recall.

+-------------------------------------------------------------------------+
|                      BISPECTRAL INDEX (BIS) SCALE                       |
+------------------+------------------------------------------------------+
| BIS Index Value  | Clinical / Electroencephalographic State             |
+------------------+------------------------------------------------------+
| **90 - 100**     | Fully awake, alert, responsive; high-frequency beta  |
| **60 - 80**      | Moderate sedation; response to loud verbal commands  |
| **40 - 60**      | **General Anesthesia Target Range**                  |
|                  | (Low awareness probability; adequate cortical sup.)  |
| **20 - 40**      | Deep hypnotic state; burst suppression pattern on EEG|
| **0 - 20**       | Profound burst suppression / isoelectric progression |
| **0**            | Completely flatline (isoelectric) EEG                |
+------------------+------------------------------------------------------+

                       [RAW EEG WAVE PROGRESSION TO BURST SUPPRESSION]

   1. Awake (Beta: >13 Hz)            wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww

   2. Light Anesthesia (Alpha: 8-12 Hz) ~\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/~

   3. Surgical Plane (Delta: 0.5-4 Hz)  ~~/\____/\____/\____/\____/\____~ governance

   4. Deep Anesthesia (Burst Suppression)  --/\/\/\/\/-------/\/\/\/\/------
                                             (Burst) (Suppression) (Burst)

Clinical Traps & Confounding Factors in Processed EEG

1. Ketamine & Nitrous Oxide Paradox: Ketamine and $N_2O$ stimulate high-frequency cortical beta oscillations, producing falsely elevated BIS numbers (e.g., 70-80) despite profound surgical anesthesia and patient unresponsiveness.
2. Electrosurgical Interference: High-frequency electrocautery currents generate radiofrequency artifacts that artificially distort BIS calculations.
3. Hypothermia & Hypoglycemia: Lower cerebral metabolic rate and slow EEG background frequencies, falsely driving the BIS score down toward burst suppression.
4. Awareness Risk Populations: Patients undergoing emergency trauma surgery, urgent Cesarean section, cardiac surgery with cardiopulmonary bypass, and those with chronic substance or opioid dependence.